AMES, Iowa, July 13 NewLink Genetics Corporation today announced that Joseph B. Saluri, J.D., has joined the company's board of directors, bringing more than a decade of experience in business development, legal and regulatory affairs, and collaborations and joint ventures.
"Joe's knowledge and experience provide a valuable asset to the company as we seek new partners to collaborate on our HyperAcute immunotherapies for treating cancers and as we work to bring our novel products to market," said Charles Link, M.D., chairman and chief executive officer of NewLink Genetics Corporation.
Mr. Saluri is currently vice president and general counsel of the Stine Group in Adel, Iowa where he works to establish collaborative marketing and research alliances with biotechnology and international agribusiness companies, in addition to managing the company's legal and intellectual property affairs. Previous to his experience with Stine, Mr. Saluri was an attorney and solicitor at law for Nicholas Critelli Associates, PC in Des Moines and London. Mr. Saluri has a B.S., B.A. in investment finance from Drake University, a Doctor of Jurisprudence from Drake University Law School and a certificate from the College of Law of England and Wales in London. Among other professional associations, he is a member of the Iowa Biotechnology Association and the Corporate Counsel Association.
About NewLink Genetics Corporation
NewLink Genetics is a private biopharmaceutical company with innovative technologies that are powering a late stage pipeline targeted at tough to treat cancers and infectious disease. NewLink's two complementary technology platforms target separate mechanisms that are commonly utilized by different cancer types to avoid immune system detection and destruction. The company's HyperAcute® cancer immunotherapy platform and its Indoleamine 2,3 Dioxygenase (IDO) program individually harness the exquisite specificity of the human immune system to selectively seek and destroy most cancer types. NewLink has four product candidates in human clinical trials, including lead candidate, HyperAcute®-Pancreas cancer immunotherapy, which is in Phase 3 testing for surgically resectable adenocarcinoma patients. The company was founded in 1999 by leading scientists from the National Cancer Institute and the National Human Genome Research Institute, combining extensive backgrounds in cancer biology, immunology, infectious disease, and molecular genetics. For more information please visit us at www.newlinkgenetics.com.
SOURCE NewLink Genetics